BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 19929861)

  • 1. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk.
    Dahl D; Hahn A; Koenecke C; Heuft HG; Dammann E; Stadler M; Buchholz S; Krauter J; Eder M; Sykora KW; Klein C; Ganser A; Sauer M
    Transfusion; 2010 Mar; 50(3):649-55. PubMed ID: 19929861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.
    Canals C; Muñiz-Díaz E; Martínez C; Martino R; Moreno I; Ramos A; Arilla M; Boto N; Pastoret C; Remacha A; Sierra J; Madoz P
    Transfusion; 2004 Nov; 44(11):1603-11. PubMed ID: 15504166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
    Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
    Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning.
    Worel N; Greinix HT; Supper V; Leitner G; Mitterbauer M; Rabitsch W; Fischer G; Rosenmayr A; Höcker P; Kalhs P
    Transfusion; 2007 Aug; 47(8):1494-502. PubMed ID: 17655594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.
    Schetelig J; Breitschaft A; Kröger N; Zabelina T; Ebell W; Bornhäuser M; Haack A; Ehninger G; Salama A; Siegert W;
    Transfusion; 2005 May; 45(5):779-87. PubMed ID: 15847669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source.
    Blin N; Traineau R; Houssin S; Peffault de Latour R; Petropoulou A; Robin M; Larghero J; Ribaud P; Socié G
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1315-23. PubMed ID: 20353831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation].
    Huang XJ; Liu DH; Xu LP; Han W; Jiang Q; Chen YH; Zhang YC; Liu KY; Bao L; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):548-50. PubMed ID: 16468333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
    Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
    Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
    Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
    Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host disease.
    Yamaguchi M; Sakai K; Murata R; Ueda M
    Bone Marrow Transplant; 2002 Oct; 30(8):539-41. PubMed ID: 12379896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation.
    Ozkurt ZN; Yegin ZA; Yenicesu I; Aki SZ; Yagci M; Sucak GT
    Transplant Proc; 2009 Nov; 41(9):3851-8. PubMed ID: 19917400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan.
    Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kobayashi T; Sato A; Iseki T; Yamaguchi T; Tojo A; Asano S
    Bone Marrow Transplant; 2007 Sep; 40(6):523-8. PubMed ID: 17646845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning.
    Hefazi M; Litzow M; Hogan W; Gastineau D; Jacob E; Damlaj M; Hashmi S; Al-Kali A; Patnaik MM
    Transfusion; 2016 Feb; 56(2):518-27. PubMed ID: 26446051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO-incompatible allogeneic haematopoietic stem cell transplantation.
    Malfuson JV; Amor RB; Bonin P; Rodet M; Boccaccio C; Pautas C; Kuentz M; Cordonnier C; Noizat-Pirenne F; Maury S
    Vox Sang; 2007 Jan; 92(1):85-9. PubMed ID: 17181595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption.
    Rabitsch W; Knöbl P; Prinz E; Keil F; Greinix H; Kalhs P; Worel N; Jansen M; Hörl WH; Derfler K
    Bone Marrow Transplant; 2003 Nov; 32(10):1015-9. PubMed ID: 14595389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation.
    Remberger M; Watz E; Ringdén O; Mattsson J; Shanwell A; Wikman A
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):675-82. PubMed ID: 17531777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.
    Kim JG; Sohn SK; Kim DH; Baek JH; Lee KB; Min WS; Kim CC; Lee MH; Lee JJ; Chung IJ; Kim HJ; Lee JW
    Bone Marrow Transplant; 2005 Mar; 35(5):489-95. PubMed ID: 15654350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different?
    Gutiérrez-Aguirre CH; Gómez-De-León A; Alatorre-Ricardo J; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; Mancías-Guerra C; Flores-Jiménez JA; Gómez-Almaguer D
    Transfusion; 2014 May; 54(5):1269-77. PubMed ID: 24898453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.